Wednesday, January 9, 2013
BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called Accurins, has entered into a global collaboration agreement with Amgen, a biotech based in Thousand Oaks, Calif., to develop and commercialize a kinase inhibitor nanomedicine for treating a range of solid tumors.
Shire, a global specialty biopharmaceutical company, has signed an agreement to acquire Lotus Tissue Repair, a Cambridge, Mass.-based biotechnology company developing the first and only protein replacement therapy currently being investigated for the treatment of dystrophic epidermolysis bullosa (DEB).
While patent expirations on many top selling medicines is spurring the research-based drug industry to embrace new development paradigms to replenish sparse R&D pipelines, drug developers need to more fully identify and address root causes of R&D inefficiency, according to the Tufts Center for the Study of Drug Development.
Cellular Dynamics International (CDI), a developer of next-generation stem cell technologies, signed a Center of Excellence agreement with global biopharmaceutical company AstraZeneca to accelerate the pace of drug discovery through the use of human induced pluripotent stem cell (iPSC) lines and tissue cells.